|
Viragen
approved to start MS clinical trials
Plantation,
Fla.
VIRAGEN Inc and Viragen (Europe) Ltd jointly announced that the
Medicines Control Agency, the governmental body that regulates therapeutic
drugs in the United Kingdom, has approved Viragen’s Application
for its natural alpha interferon, Omniferon, to commence human clinical
trials for the treatment of multiple sclerosis.
Omniferon is currently in phase II clinical trials in Europe for
hepatitis C. The multiple sclerosis clinical trials are expected
to begin later this year. Additional evaluations are ongoing to
determine Omniferon’s potential for the treatment of genital
herpes and many cancers. Dr Peng Lee Yap, Viragen’s Chief Medical
Director, said, ‘‘The approval of our Application enables
us to start the administration of Omniferon to multiple sclerosis
(MS) patients as part of Viragen’s development plans to gain
marketing authorization for the routine treatment of MS with Omniferon.
The phase II (a) clinical trial will focus on demonstrating the
safety and tolerance of different doses of Omniferon in such patients.’’
Viragen’s chairman and CEO, Gerald Smith, stated, ‘‘This
approval marks an important milestone which targets a second billion
dollar market for the use of Omniferon.
PRNewswire
|
